VSMART - Antoni, Michael
-
Investigator:
Michael Antoni
Email
Coordinator:
IRB: 20160525
SDG: Population Sciences
Disease Site(s): Breast
Sponsor: Florida Biomedical Research Program
Enrolling Sites:
JMH
SylvesterTitle: Stress Management Effects on Affective Status and Influenza Vaccine Response in Older Breast Cancer Patients.
Eligibility Criteria - NCT03955991 *This information has been extracted from " www.clinicaltrials.gov"
TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20201046 - Calfa Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Deborah Conte
9542101171
IRB: 20201046
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: ETCTN
Enrolling Sites:
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Eligibility Criteria - NCT04090398 *This information has been extracted from " www.clinicaltrials.gov"
20210993 - Calfa Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Deborah Conte
9542101171
IRB: 20210993
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: BRIACELL
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab and Epacadostat
Eligibility Criteria - NCT03328026 *This information has been extracted from " www.clinicaltrials.gov"
CompassHER2-pCR - Dawar, Richa
-
Investigator:
Richa Dawar
Email
Coordinator:
IRB: 20200685
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: ECOG
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
Eligibility Criteria - NCT04266249 *This information has been extracted from " www.clinicaltrials.gov"
20200613 - Escobar Mauricio
-
Investigator:
Mauricio Escobar
Email
Coordinator:
IRB: 20200613
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: Hoffmann - La Roche
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer
Eligibility Criteria - NCT04546009 *This information has been extracted from " www.clinicaltrials.gov"
MATCH - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20150671
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
Sponsor: ECOG
Enrolling Sites:
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: Molecular Analysis for Therapy Choice (MATCH)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"
20201540 - Kesmodel Susan
-
Investigator:
Susan Kesmodel
Email
Coordinator: Jornan Rodriguez Leyva
+1 (305) 2432871
IRB: 20201540
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: SCCC
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: Prospective Evaluation of Targeted Axillary Dissection After Neoadjuvant Systemic Therapy in Patients with Breast Cancer with Advanced Nodal Disease at Diagnosis
Eligibility Criteria - NCT04998682 *This information has been extracted from " www.clinicaltrials.gov"
20210732 - Krill Jackson Elisa
-
Investigator:
Elisa Krill Jackson
Email
Coordinator:
IRB: 20210732
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: Veru Inc.
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining =40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 inhibitor
Eligibility Criteria - NCT04869943 *This information has been extracted from " www.clinicaltrials.gov"
RTX-240-01 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20200686
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Multiple
Sponsor: Rubius Therapeutics
Enrolling Sites:
Sylvester
Title: PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"
20201537 - O'Neil Daniel
-
Investigator:
Daniel O'Neil
Email
Coordinator:
IRB: 20201537
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: Olema Pharmaceuticals
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer
Eligibility Criteria - NCT04505826 *This information has been extracted from " www.clinicaltrials.gov"
Tbio-6517-ITu-001 - Pimentel, Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20200277
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: TSB
Enrolling Sites:
Sylvester
Title: A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"
RPL-001-16 - Rodriguez, Estelamari
-
Investigator:
Estelamari Rodriguez
Email
Coordinator: Yanel Diaz Caro
3052438227
IRB: 20180802
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bladder,Breast-Female,Colon,Melanoma, skin
Sponsor: REPLIMUNE
Enrolling Sites:
Sylvester
Title: RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"
SABER Study - Takita, Cristiane
-
Investigator:
Cristiane Takita
Email
Coordinator: Zuzel Rodriguez
+1 (305) 2430124
IRB: 20190283
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: SCCC
Enrolling Sites:
Sylvester
Title: Phase I Study to Evaluate the Safety and Feasibility of Preoperative Ablative Breast Radiotherapy (SABER) for Selected Early Stage Breast Cancer
Eligibility Criteria - NCT04360330 *This information has been extracted from " www.clinicaltrials.gov"
MA.39: TAILOR RT - Takita, Cristiane
-
Investigator:
Cristiane Takita
Email
Coordinator: Zuzel Rodriguez
+1 (305) 2430124
IRB: 20190405
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: CCTG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Eligibility Criteria - NCT03488693 *This information has been extracted from " www.clinicaltrials.gov"
20220017 - Takita Cristiane
-
Investigator:
Cristiane Takita
Email
Coordinator: Samantha St. Armand
IRB: 20220017
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: NRG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer
Eligibility Criteria - NCT04852887 *This information has been extracted from " www.clinicaltrials.gov"
20210118 - Valdes Frances
-
Investigator:
Frances Valdes
Email
Coordinator:
IRB: 20210118
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling Sites:
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Eligibility Criteria - NCT04457596 *This information has been extracted from " www.clinicaltrials.gov"
20210996 - Valdes Frances
-
Investigator:
Frances Valdes
Email
Coordinator:
IRB: 20210996
SDG: Breast Cancer
Disease Site(s): Breast
Sponsor: Orinove Inc
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects With Solid Tumors.
Eligibility Criteria - NCT03950570 *This information has been extracted from " www.clinicaltrials.gov"